131 completed, 71 unknown, 32 recruiting, 21 terminated. 295 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 295 | Completed 131, Unknown 71, Recruiting 32, Terminated 21, Not yet recruiting 16, Active not recruiting 11, Withdrawn 11, Enrolling by invitation 2 |
Follow Lymphoproliferative Disorders: new trials by email Literature Review of Lymphoproliferative Disorders trials Research Report on Lymphoproliferative Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases. teclistamab OR talquetamab OR elranatamab OR linvoseltamab, BTK inhibitors (ibrutinib and zanubrutinib) - Waldenstrom Macroglobulinaemia, Multiple Myeloma | Phase 4 | Not yet recruiting | Anne Louise Tølbøll Sørensen | 400 | 2027-03-01 | 2026-03-16 |
| Self-administered Subcutaneous Daratumumab in Patients With Multiple Myeloma The study intervention is self-administration of SC daratumumab by the patient, thereby changing the administration from an outpatient setting to a home setting. - Multiple Myeloma in Relapse | Phase 4 | Not yet recruiting | Odense University Hospital | 50 | 2026-11-01 | 2026-10-21 |
| A Phase IV Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma That is Not Responding to Four or More Standard Treatments or Has Come Back After Several Standard Treatments Elranatamab - Relapsed/Refractory Multiple Myeloma, Multiple Myeloma | Phase 4 | Not yet recruiting | Pfizer | 75 | 2026-10-22 | 2026-10-19 |
| Gabapentin vs. Benzonatate vs. Standard of Care for Cough in ILD Gabapentin, Benzonatate 200 mg, Standard of care treatment for ILD - Interstitial Lung Disease | Phase 4 | Not yet recruiting | Post Graduate Institute of Medical Education and Research, Chandigarh | 177 | 2026-10-07 | 2026-10-08 |
| Pomalidomide Plus Rituximab Maintenance in Young High-Risk Newly Diagnosed DLBCL After First-Line Response Pomalidomide, Rituximab - Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 4 | Not yet recruiting | The First Hospital of Jilin University | 27 | 2026-09-01 | 2026-08-12 |
| Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS) Linvoseltamab, Tocilizumab - Relapsed/Refractory Multiple Myeloma (RRMM) | Phase 4 | Recruiting | Regeneron Pharmaceuticals | 30 | 2026-07-15 | 2026-10-27 |
| Optimizing Preeclampsia Postpartum With Point-of-care Ultrasound Butterfly iQ3 ultrasound system for determination of postpartum volume status, Oral furosemide, Intravenous furosemide - Preeclampsia, Preeclampsia Postpartum | Phase 4 | Not yet recruiting | University of California, Irvine | 96 | 2026-06-15 | 2026-01-23 |
| Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy Cosibelimab, Prednisone, Sirolimus - Cutaneous Squamous Cell Carcinoma, Skin Cancer | Phase 4 | Recruiting | Dana-Farber Cancer Institute | 80 | 2026-04-23 | 2026-08-11 |
| A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Pirtobrutinib, Idelalisib - Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic | Phase 4 | Recruiting | Eli Lilly and Company | 150 | 2026-03-09 | 2026-09-22 |
| Isa-VRD in TIE HRMM Isatuximab, bortezomib, lenalidomide, dexamethason, Bortezomib, Lenalidomide, Dexamethasone - Multiple Myeloma | Phase 4 | Not yet recruiting | Peking Union Medical College Hospital | 117 | 2026-01-30 | 2026-01-13 |
| Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager Target trough IgG level of 8-10 g/L, Target trough IgG level 4-6 g/L, No history of recurrent or severe infections and total IgG level higher or equal at 4 g/L - Multiple Myeloma Refractory, Relapsed Multiple Myeloma | Phase 4 | Recruiting | CHU de Quebec-Universite Laval | 80 | 2026-01-05 | 2026-07-22 |
| Levofloxacin Prophylaxis to Prevent First Febrile Neutropenia in Pediatric ALL During Induction Phase Levofloxacin, Placebo - Neutropenic Fever, Acute Lymphoblastic Leukemia | Phase 4 | Terminated | Gadjah Mada University | 49 | 2026-01-01 | 2026-10-01 |
| ZSDT for the Treatment of R/R Mantle Cell Lymphoma After BTK Inhibitor Failure: a Multi-center Prospective Clinical Trial ZSDT regimen - Mantle Cell Lymphoma (MCL) | Phase 4 | Not yet recruiting | Zhengzhou University | 30 | 2025-12-31 | 2025-12-04 |
| Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma Orelabrutinib - Marginal Zone Lymphoma(MZL) | Phase 4 | Recruiting | Beijing Tongren Hospital | 88 | 2025-11-25 | 2026-01-21 |
| Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma Rituximab, Zanubrutinib - Hemophagocytic Lymphohistiocytosis, B Cell Lymphoma | Phase 4 | Recruiting | The First Affiliated Hospital of Soochow University | 40 | 2025-11-01 | 2025-12-08 |
| A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström Macroglobulinemia Zanubrutinib - Waldenström's Macroglobulinemia | Phase 4 | Active not recruiting | BeiGene | 16 | 2025-10-17 | 2026-08-10 |
| Beyond EOsinophils: proteoMICS to Identify Potential Biomarker of Organ Damage and Response to MEPOLIZUMAB in EGPA Mepolizumab 100 MG Injection [Nucala], Mepolizumab 300 mg - EGPA - Eosinophilic Granulomatosis With Polyangiitis, Severe Asthma | Phase 4 | Enrolling by invitation | Azienda Ospedaliero Universitaria di Cagliari | 90 | 2025-10-17 | 2026-01-15 |
| Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial Acetaminophen, Biospecimen Collection, Dexamethasone - Multiple Myeloma | Phase 4 | Recruiting | Emory University | 94 | 2025-09-24 | 2026-07-23 |
| Bioequivalence Studies of Dasatinib 100 Mg Dasatinib 100 MG - Myeloma Multiple | Phase 4 | Not yet recruiting | Centro de Atencion e Investigacion Medica | 46 | 2025-09-01 | 2025-02-12 |
| Fenofibrate Role in the Prophylaxis From Peripheral Neuropathy Induced by Bortezomib, Lenalidomide and Dexamethasone (VRd) Protocol in the Treatment of Patients With Multiple Myeloma (MM) Bortezomib + Lenalidomide + Dexamethasone + Fenofibrate 160 mg tablet, Bortezomib + Lenalidomide + Dexamethasone - Peripheral Neuropathy, Multiple Myeloma, Neoplasms | Phase 4 | Recruiting | Tanta University | 44 | 2025-08-30 | 2025-11-04 |
Showing 20 of 295. Sign in to see all of them.
Precursor Cell Lymphoblastic Leukemia-Lymphoma (60) · Multiple Myeloma (54) · Lymphoma (35) · Lymphoma, Follicular (31) · Lymphoma, Non-Hodgkin (30) · Sarcoidosis (18) · Leukemia, Lymphocytic, Chronic, B-Cell (16) · Recurrence (14) · Lymphoma, Large B-Cell, Diffuse (12) · Leukemia (11) · Lymphoma, B-Cell (10) · Hodgkin Disease (8) · Lymphoma, T-Cell, Cutaneous (8) · Waldenstrom Macroglobulinemia (8) · Neoplasms (7)
Hemic and Lymphatic Diseases (294) · Immune System Diseases (292) · Immunoproliferative Disorders (267) · Neoplasms by Histologic Type (263) · Neoplasms (259) · Lymphatic Diseases (242) · Hematologic Diseases (152) · Lymphoma (105) · Leukemia, Lymphoid (79) · Leukemia (75) · Lymphoma, Non-Hodgkin (75) · Cardiovascular Diseases (68) · Vascular Diseases (67) · Blood Protein Disorders (61)
Cyclophosphamide (32) · Dexamethasone (32) · Vincristine (24) · Methotrexate (23) · Rituximab (22) · Cytarabine (21) · Doxorubicin (17) · Mercaptopurine (16) · Prednisone (15) · Asparaginase (13) · Bortezomib (12) · Daunorubicin (12) · Prednisolone (12) · Etoposide (11) · Granulocyte Colony-Stimulating Factor (11)
PETHEMA Foundation (11) · Peking University (7) · University of Cincinnati (7) · Mingzhi Zhang (6) · Pfizer (6) · Ruijin Hospital (6) · Zhengzhou University (6) · Goethe University (5) · Hoffmann-La Roche (5) · Institute of Hematology & Blood Diseases Hospital, China (5) · Novartis Pharmaceuticals (5) · Peking Union Medical College Hospital (5) · Shandong Provincial Hospital (5) · Takeda (5) · Eisai Inc. (4)
China (80) · United States (75) · Spain (29) · Germany (20) · France (19) · Italy (19) · United Kingdom (16) · Canada (12) · Poland (12) · Australia (11) · India (11) · Russia (11) · Sweden (10) · Czechia (9) · Taiwan (9)
Robert P Baughman, MD (6) · Dieter Hoelzer, MD,PhD (4) · Shuhua Yi, Doc (4) · Jun Zhu (3) · Jun Zhu, MD (3)
PMID 32632956, PMID 19144982, PMID 22442346, PMID 22493293, PMID 23024237, PMID 23770157, PMID 27561722, PMID 28751559, PMID 11863096, PMID 14585365, PMID 14752084, PMID 15014526, PMID 15158091, PMID 15225842, PMID 15257960, PMID 15770833, PMID 16648042, PMID 17223475, PMID 17410187, PMID 18165618, PMID 18240234, PMID 18263672, PMID 18626005, PMID 19167677, PMID 19219604, PMID 19246088, PMID 19564304, PMID 19951974, PMID 20118030, PMID 20560291, PMID 20660832, PMID 21575927, PMID 21828124, PMID 21890336, PMID 21912321, PMID 21932110, PMID 21940824, PMID 22198540, PMID 22443312, PMID 22677206, PMID 22966847, PMID 23275102, PMID 23317527, PMID 23383989, PMID 23446769, PMID 23590801, PMID 23615461, PMID 23753028, PMID 23775967, PMID 23775972
2009 (4), 2018 (2), 2019 (2), 2023 (2), 2005 (1), 2014 (1), 2016 (1), P01CA128115 (1), P30CA021765 (1), P30CA138292 (1), R01CA078957 (1), U01CA081445 (1)